Click here for printer friendly page
Life sciences have appeal for venture capitalists16/05/2005. Source: Israel Venture Capital Journal.
 The IVCJ talks to Kenneth Abramowitz, Managing General
Partner of NGN Capital, about what the IPO window is like right now for life science companies and what markets, management and technology appeals to VCs.
How do life science investors view the current investment environment?
The Israeli Venture Capital Journal turned to Kenneth Abramowitz, Managing General Partner of NGN (New Global Network) Capital for his perspective.
Click here to view full article (pdf 63kb) You need Adobe Acrobat to read this document. If you do not have it, you can download it free from www.adobe.com/products/acrobat/readstep.html
This article first appeared in the Israel Venture Capital & Private Equity Journal. IVC Research Center publishes the Israel Venture Capital & Private Equity Journal (IVCJ), a quarterly review of trends and developments in the Israeli-related venture capital industry. IVCJ, distributed worldwide, is dedicated to provide wide-range coverage of Israel's venture capital industry. For more information please visit http://www.ivc-online.com
|
